Sanofi SA has discontinued the sale of its generic version of Lovenox (enoxaparin), a drug authorised for the treatment of deep vein thrombosis, the company said in a letter to its customers.

Duane Nash, an analyst at Wedbush Securities told the International Business Times, “Lovenox should be more profitable to Sanofi without an authorized generic, provided that Momenta Pharmaceuticals Inc’s M-Enox remains the sole third-party generic.”

Nash added that the announcement was expected after a Massachusetts court injunction prevented sales of Amphastar’s generic enoxaparin.

The injunction was requested by Amphastar and Sandoz, a generic drug manufacturer based in Germany.

Amphastar’s enoxaparin is expected to continue to be profitable if other generics remain off the market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Caption: Sanofi’s generic version of Lovenox has been approved for the treatment of DVT and pulmonary embolisms.